TABLE 3.
Summary of Studies Managing Acute Muscular Hamstring Injury Using PRP or Autologous Conditioned Serum a
| Additional Outcomes | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Lead Author (Year) | Risk of Bias b | Injury Type | Intervention | N | Mean ± SD Time to RTP, d | Reinjury Rate, % | Mean Follow-up, mo | Hamstring Strength | Hamstring ROM |
| A Hamid (2014) 1 | Low | Grade 1 | (1) PRP (1 × 3-mL direct injection 5 d postinjury (2) No injection |
14 14 |
26.7 ± 7.0
c
42.5 ± 20.6 c |
— | — | X | |
| Bezuglov (2019) 16 | Low | BAMIC 2a/2b | (1) PRP (1 × 8-mL direct injection <48 h postinjury) (2) Saline (1 × 8-mL direct injection <48 h postinjury) |
20 20 |
11.4 ± 1.2
c
21.3 ± 2.7 c |
0.0 0.0 |
6 | ||
| Bradley (2020) 21 | 18 (24) | Cohen grade 2 | (1) PRP (1-3 × 2- to 5-mL direct injections 1 wk apart) (2) No injection |
30 39 |
22.5 ± 20.1 25.7 ± 20.6 |
3.3 2.6 |
— | ||
| Gaballah (2018) 33 | Low | Grade 2 | (1) PRP (1 × 3-mL direct injection, 5-7 d postinjury) (2) No injection |
8 9 |
Maximum, 27
c
Maximum, 43 c |
— | — | X | |
| Guillodo (2015) 37 | 19 (24) | Grade 3 | (1) PRP (1 × 3-mL direct injection <8 d postinjury) (2) No injection |
15 19 |
50.9 ± 10.7 52.8 ± 15.7 |
— | — | ||
| Hamilton (2015) 39 | Low | Grade 1-2 | (1) PRP (3 × 1-mL injections 1 cm apart, <5 d postinjury) (2) PPP (3 × 1-mL injections 1 cm apart, <5 d postinjury) (3) No injection |
30 30 30 |
21 (95% CI, 18-24)
c
27 (95% CI, 21-33) c 25 (95% CI, 22-29) |
7.7 10.7 10.3 |
6 | X | |
| Lee (2020) 50 | 12 (16) | Grade 1-3 | PRP (single injection) | 8 | 49 (range, 10-112) | — | — | ||
| Rettig (2013) 65 | 18 (24) | Grade 1-2 | (1) PRP (1 × 9-mL direct injection <48 h postinjury) (2) No injection |
5 5 |
20 (range, 16-30) 17 (range, 8-81) |
— | — | ||
| Reurink (2015) 66 | Low | Grade 1-2 | (1) PRP (3 × 1-mL injections 1 cm apart at 5 and 10 d postinjury) (2) Saline (3 × 1-mL injections 1 cm apart at 5 and 10 d postinjury) |
41 39 |
42 (IQR, 30-58) 42 (IQR, 37-56) |
27.0 29.7 |
12 | X | X |
| Wright-Carpenter (2004) 88 | 19 (24) | Grade 2 | (1) Autologous conditioned serum (5 × 1-mL injections over area of injury every 2nd day [mean, 5.4 injections]) (2) Actovegin/Traumeel therapy (5 × 1-mL injections over area of injury every second day [mean, 8.3 injections]) |
6 5 |
16.3 ± 3.1
c
21.8 ± 4.8 c |
— | — | ||
| Zanon (2016) 89 | 12 (16) | Grade 2 | PRP (2-3 × 3-mL injections at 72 h and 7 d postinjury) | 25 | 35.1 ± 18.9 | 12.0 | 37 | ||
a Dashes indicate data not reported. BAMIC, British Athletics Muscle Injury Classification; IQR, interquartile range; PPP, platelet-poor plasma; PRP, platelet-rich plasma; ROM, range of motion; RTP, return to play; X, outcome(s) reported.
b Reported as Methodological Index for Non-Randomized Studies score (maximum score) for nonrandomized studies or Cochrane Risk-of-Bias Tool for Randomized Trials.
c Significant difference between interventions (P < .05).